

Allegato 5: valutazione premialità pubblicazioni

Cognome Nome	Ruolo	SSD	Handle IRIS	Anno	Titolo	Note	Punti quartile	Punti autorialità	Riduzione + di 10 autori =puntix0,5	Riduzione review	Totale	Punti pubblicazioni	Punteggio ricercatore	Finanziamento
Amparore Daniele	RTDB	MED/24	2318/1828879	2021	Three-dimensional Virtual Models' Assistance During Minimally Invasive Partial Nephrectomy Minimizes the Impairment of Kidney Function	Fondi attivi = non si applica moltiplicatore + first	3	1			4	32	32	7.281,92 €
Amparore Daniele	RTDB	MED/24	2318/1738064	2020	Assessing the Burden of Nondeferrable Major Uro-oncologic Surgery to Guide Prioritisation Strategies During the COVID-19 Pandemic: Insights from Three Italian High-volume Referral Centres	Co-first	3	1			4			0,00 €
Amparore Daniele	RTDB	MED/24	2318/1738093	2020	Impact of the COVID-19 pandemic on urology residency training in Italy.	Fist e corresponding	2	1			3			0,00 €
Amparore Daniele	RTDB	MED/24	2318/1710001	2018	3-Year follow-up of temporary implantable nitinol device implantation for the treatment of benign prostatic obstruction.	LAST	3	1			4			0,00 €
Amparore Daniele	RTDB	MED/24	2318/1881124	2022	Three-dimensional imaging reconstruction of the kidney's anatomy for a tailored minimally invasive partial nephrectomy: A pilot study	FIRST	1	1			2			0,00 €
Amparore Daniele	RTDB	MED/24	2318/1889766	2022	Indocyanine Green Drives Computer Vision Based 3D Augmented Reality Robot Assisted Partial Nephrectomy: The Beginning of "Automatic" Overlapping Era	FIRST	1	1			2			0,00 €
Amparore Daniele	RTDB	MED/24	2318/1881153	2022	Identification of Recurrent Anatomical Clusters Using Three-dimensional Virtual Models for Complex Renal Tumors with an Imperative Indication for Nephron-sparing Surgery: New Technological Tools for Driving Decision-making	FIRST	0,5	0,5			1			0,00 €
Amparore Daniele	RTDB	MED/24	2318/1870380	2021	Comparison between minimally-invasive partial and radical nephrectomy for the treatment of clinical T2 renal masses: results of a 10-year study in a tertiary care center	FIRST	3	1			4			0,00 €
Amparore Daniele	RTDB	MED/24	2318/1870381	2021	3-Year results following treatment with the second generation of the temporary implantable nitinol device in men with LUTS secondary to benign prostatic obstruction	FIRST	3	1			4			0,00 €
Amparore Daniele	RTDB	MED/24	2318/1870382	2021	3D imaging technologies in minimally invasive kidney and prostate cancer surgery: which is the urologists' perception?	FIRST	3	1			4			0,00 €
Arena Sabrina	PA	BIO/17	2318/1872758	2022	Targeting the DNA Damage Response pathways and Replication Stress in Colorectal Cancer.	Fondi attivi = non si applica moltiplicatore + Last	3	1			4	29	29	6.599,24 €
Arena Sabrina	PA	BIO/17	2318/1796060	2021	Empowering clinical decision-making in oligometastatic colorectal cancer: the potential role of drug screening of patient-derived organoids	co-last and corresponding	2	1			3			0,00 €
Arena Sabrina	PA	BIO/17	2318/1792656	2021	Preclinical models as patients' avatars for precision medicine in colorectal cancer: past and future challenges.	last and corresponding	3	1		0,5	2			0,00 €
Arena Sabrina	PA	BIO/17	2318/1764704	2020	The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer.	co-first and co-corresponding	3	1			4			0,00 €
Arena Sabrina	PA	BIO/17	2318/1738329	2020	Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer.	last and corresponding	2	1			3			0,00 €
Arena Sabrina	PA	BIO/17	2318/1728652	2020	A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin. Clin Cancer Res.	first	3	1			4			0,00 €
Arena Sabrina	PA	BIO/17	2318/1715076	2019	Patient-derived xenografts and matched cell lines identify pharmacogenomic vulnerabilities in colorectal cancer.	last and corresponding	3	1			4			0,00 €

Allegato 5: valutazione premialità pubblicazioni

Cognome Nome	Ruolo	SSD	Handle IRIS	Anno	Titolo	Note	Punti quartile	Punti autorialità	Riduzione + di 10 autori =puntix0,5	Riduzione review	Totale	Punti pubblicazioni	Punteggio ricercatore	Finanziamento
Arena Sabrina	PA	BIO/17	2318/1689587	2018	Characterization of tumor-derived mesenchymal stem cells potentially differentiating into cancer-associated fibroblasts in lung cancer.	First	1	1			2			0,00 €
Arena Sabrina	PA	BIO/17	2318/1792657	2021	Werner helicase is a synthetic-lethal vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy and Immunotherapy	middle	3		0,5		1,5			0,00 €
Arena Sabrina	PA	BIO/17	2318/1740015	2020	EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer	middle	3		0,5		1,5			0,00 €
Astanina Elena	RUTDA	BIO/10	2318/1877590	2022	The TFEB-TGIF1 axis regulates EMT in mouse epicardial cells	No fondi attivi alla scadenza del bando + first, corresponding	3	1			4	18,5	23,125	5.262,33 €
Astanina Elena	RUTDA	BIO/10	2318/1877591	2022	Transcription factor EB controls both mitogenic and mitogenic cell activities.	first	2	1			3			
Astanina Elena	RUTDA	BIO/10	2318/1871099	2022	TFEB controls integrin-mediated endothelial cell adhesion by the regulation of cholesterol metabolism		3				3			
Astanina Elena	RUTDA	BIO/10	2318/1870487	2022	Role of TGFβ1 and WNT6 in FGF2 and BMP4-driven endothelial differentiation of murine embryonic stem cells		3				3			
Astanina Elena	RUTDA	BIO/10	2318/1936790	2021	miR-200c-3p Regulates Epithelial-to-Mesenchymal Transition in Epicardial Mesothelial Cells by Targeting Epicardial Follistatin-Related Protein 1		2		0,5		1			
Astanina Elena	RUTDA	BIO/10	2318/1789507	2021	The Oncogene Transcription Factor EB Regulates Vascular Functions		2			0,5	1			
Astanina Elena	RUTDA	BIO/10	2318/1788049	2021	Multifaceted activities of transcription factor EB in cancer onset and progression	first	3	1		0,5	2			
Astanina Elena	RUTDA	BIO/10	2318/1685458	2019	TFEB controls vascular development by regulating the proliferation of endothelial cells		3		0,5		1,5			
Astanina Elena	RUTDA	BIO/10												
Astanina Elena	RUTDA	BIO/10												
Balbi Maurizio	RUTDA	MED/36	2318/1893473	2023	Automated Coronary Artery Calcium and Quantitative Emphysema in Lung Cancer Screening: Association With Mortality, Lung Cancer Incidence, and Airflow Obstruction	No fondi attivi alla scadenza del bando + First	2	1			3	16,5	0	0,00 €
Balbi Maurizio	RUTDA	MED/36	2318/1894948	2021	Post-discharge chest CT findings and pulmonary function tests in severe COVID-19 patients	First	2	1			3			
Balbi Maurizio	RUTDA	MED/36	2318/1895194	2021	Chest X-ray for predicting mortality and the need for ventilatory support in COVID-19 patients presenting to the emergency department	First	3	1			4			
Balbi Maurizio	RUTDA	MED/36	2318/1899732	2021	How imaging should properly be used in COVID-19 outbreak: an Italian experience	Last. Note, editorial material	0	0			0			
Balbi Maurizio	RUTDA	MED/36	2318/1903933	2023	Fully automated calcium scoring predicts all-cause mortality at 12 years in the MILD lung cancer screening trial	Second	2				2			
Balbi Maurizio	RUTDA	MED/36	2318/1894752	2022	Cerebral superb microvascular imaging in preterm neonates: in vivo evaluation of thalamic, striatal, and extraatrial angioarchitecture	Second	1		0,5		0,5			
Balbi Maurizio	RUTDA	MED/36	2318/1893474	2022	Interstitial lung abnormalities: new insights between theory and clinical practice	Fifth	2				2			
Balbi Maurizio	RUTDA	MED/36	2318/1894760	2021	Imaging in non-cystic fibrosis bronchiectasis and current limitations	Join first. Review.	1	1		0,5	1			
Balbi Maurizio	RUTDA	MED/36	2318/1893551	2022	The radiological appearances of lung cancer treated with immunotherapy	Fourth	1				1			
Balbi Maurizio	RUTDA	MED/36	2318/1894942	2020	Integrated Radiologic Algorithm for COVID-19 Pandemic	Fourth. Note, editorial material	0	0			0			

Allegato 5: valutazione premialità pubblicazioni

Cognome Nome	Ruolo	SSD	Handle IRIS	Anno	Titolo	Note	Punti quartile	Punti autorialità	Riduzione + di 10 autori =puntix0,5	Riduzione review	Totale	Punti pubblicazioni	Punteggio ricercatore	Finanziamento
Bersani Francesca	RTDA	BIO/10	2318/1794750	2020	Future perspectives from lung cancer pre-clinical models: new treatments are coming?	SI fondi attivi alla scadenza del bando + First	2	1		0,5	1,5	15	15	3.413,40 €
Bersani Francesca	RTDA	BIO/10	2318/1794956	2020	Water and microbial monitoring technologies towards the near future space exploration	\	3			0,5	1,5			0,00 €
Bersani Francesca	RTDA	BIO/10	2318/1794730	2020	Water disinfection by orifice-induced hydrodynamic cavitation	\	3				3			0,00 €
Bersani Francesca	RTDA	BIO/10	2318/1794732	2020	Techno-economic analysis of a solar thermal plant for large-scale water pasteurization	\	1				1			0,00 €
Bersani Francesca	RTDA	BIO/10	2318/1794764	2019	Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer	\	3		0,5		1,5			0,00 €
Bersani Francesca	RTDA	BIO/10	2318/1794753	2018	Screening and risk management solutions for steroidal estrogens in surface and wastewater	\	3			0,5	1,5			0,00 €
Bersani Francesca	RTDA	BIO/10	2318/1794925	2018	Effect-based and chemical analytical methods to monitor estrogens under the European Water Framework Directive	\	3			0,5	1,5			0,00 €
Bersani Francesca	RTDA	BIO/10	2318/1794729	2018	Water quality and total microbial load: A double-threshold identification procedure intended for space applications	\	2				2			0,00 €
Bersani Francesca	RTDA	BIO/10	2318/1794754	2018	AR expression in breast cancer CTCs associates with bone metastases	\	3		0,5		1,5			0,00 €
Bersani Francesca	RTDA	BIO/10												0,00 €
Bironzo Paolo	RTDB	MED/06	2318/1689558	2018	Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification.	Fondi attivi	3		0,5		1,5	22	22	5.006,32 €
Bironzo Paolo	RTDB	MED/06	2318/1685285	2018	Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis.		3		0,5		1,5			0,00 €
Bironzo Paolo	RTDB	MED/06	2318/1790638	2021	Clinical and Molecular Features of Epidermal Growth Factor Receptor (EGFR) Mutation Positive Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors (TKIs): Predictive and Prognostic Role of Co-Mutations.	First author	2	1			3			0,00 €
Bironzo Paolo	RTDB	MED/06	2318/1793555	2021	Descriptive Comparative Analysis of Patients With Cancer Referring to the Emergency Department of an Italian University Hospital Across the Severe Acute Respiratory Syndrome Coronavirus 2 Waves.	corresponding	2	1			3			0,00 €
Bironzo Paolo	RTDB	MED/06	2318/1848740	2022	A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma	joint first	3	1		0,5	2			0,00 €
Bironzo Paolo	RTDB	MED/06	2318/1874007	2022	Clinical-Molecular Prospective Cohort Study in Non-Small Cell Lung Cancer (PROMOLE study): A Comprehensive Approach to Identify New Predictive Markers of Pharmacological Response	First author	2	1			3			0,00 €
Bironzo Paolo	RTDB	MED/06	2318/1878034	2022	Comparing T Cell Subsets in Broncho-Alveolar Lavage (BAL) and Peripheral Blood in Patients with Advanced Lung Cancer	Co-Last author	2	1			3			0,00 €
Bironzo Paolo	RTDB	MED/06	2318/1873921	2022	Immunohistochemistry with 3 different clones in anaplastic lymphoma kinase fluorescence in situ hybridization positive non-small-cell lung cancer with thymidylate synthase expression analysis: a multicentre, retrospective, Italian study	First author	1	1			2			0,00 €
Bironzo Paolo	RTDB	MED/06	2318/1693693	2018	Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016.		3			0,5	1,5			0,00 €

Allegato 5: valutazione premialità pubblicazioni

Cognome Nome	Ruolo	SSD	Handle IRIS	Anno	Titolo	Note	Punti quartile	Punti autorialità	Riduzione + di 10 autori =puntix0,5	Riduzione review	Totale	Punti pubblicazioni	Punteggio ricercatore	Finanziamento
Bironzo Paolo	RTDB	MED/06	2318/1703925	2019	Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.		3		0,5		1,5			0,00 €
Buccinnà Barbara	TR		2318/1686360	2018	Targeting Myeloid Differentiation Using Potent 2-Hydroxypyrazolo[1,5- a]pyridine Scaffold-Based Human Dihydroorotate Dehydrogenase Inhibitors	No fondi attivi	3		0,5		1,5	7,5	9,375	2.133,38 €
Buccinnà Barbara	TR		2318/1795212	2021	Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold: SAR of the Biphenyl Moiety		3		0,5		1,5			0,00 €
Buccinnà Barbara	TR		2318/1878289	2022	Targeting Acute Myelogenous Leukemia Using Potent Human Dihydroorotate Dehydrogenase Inhibitors Based on the 2-Hydroxypyrazolo[1,5-a]pyridine Scaffold: SAR of the Aryloxyaryl Moiety		3		0,5		1,5			0,00 €
Buccinnà Barbara	TR		2318/1891099	2022	AMPK activation attenuates HER3 upregulation and Neuregulin-Mediated rescue of cell proliferation in HER2-Overexpressing breast cancer cell lines exposed to lapatinib	first author	2	1			3			0,00 €
Buccinnà Barbara	TR													0,00 €
Buccinnà Barbara	TR													0,00 €
Buccinnà Barbara	TR													0,00 €
Buccinnà Barbara	TR													0,00 €
Buccinnà Barbara	TR													0,00 €
Buccinnà Barbara	TR													0,00 €
Buccinnà Barbara	TR													0,00 €
Comunanza Valentina	RTDB	BIO/10	2318/1653399	2018	Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment	No fondi attivi	2		0,5		1	18,5	23,125	5.262,33 €
Comunanza Valentina	RTDB	BIO/10	2318/1662906	2018	PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations article		2				2			0,00 €
Comunanza Valentina	RTDB	BIO/10	2318/1685458	2019	TFEB controls vascular development by regulating the proliferation of endothelial cells		3		0,5		1,5			0,00 €
Comunanza Valentina	RTDB	BIO/10	2318/1711992	2019	Potential diagnostic and prognostic role of micro-environment in malignant pleural mesothelioma		3		0,5		1,5			0,00 €
Comunanza Valentina	RTDB	BIO/10	2318/1711962	2020	Wnt/IL-18/IL-8 autocrine circuitries control chemoresistance in mesothelioma initiating cells by inducing ABCB5		2		0,5		1			0,00 €
Comunanza Valentina	RTDB	BIO/10	2318/1789506	2021	The role of redox system in metastasis formation	Joint first	3	1		0,5	2			0,00 €
Comunanza Valentina	RTDB	BIO/10	2318/1790637	2021	Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma		2		0,5		1			0,00 €
Comunanza Valentina	RTDB	BIO/10	2318/1845838	2022	SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma		3		0,5		1,5			0,00 €
Comunanza Valentina	RTDB	BIO/10	2318/1906773	2023	Dual VEGFA/BRAF targeting boosts PD-1 blockade in melanoma through GM-CSF-mediated infiltration of M1 macrophages	First author, corresponding	3	1			4			0,00 €
Comunanza Valentina	RTDB	BIO/10	2318/1906774	2023	TFEB inhibition induces melanoma shut-down by blocking the cell cycle and rewiring metabolism		3				3			0,00 €
D'Ambrosio Lorenzo	RTDB	MED/06	2318/1877300	2022	New benchmarks to design clinical trials with advanced or metastatic liposarcoma or synovial sarcoma patients: An EORTC - Soft Tissue and Bone Sarcoma Group (STBSG) meta-analysis based on a literature review for soft-tissue sarcomas.	SI fondi + middle	2			0,5	1	24	24	5.461,44 €
D'Ambrosio Lorenzo	RTDB	MED/06	2318/1877303	2022	First and further-line multidisciplinary treatment of retroperitoneal sarcomas	first	1	1		0,5	1			0,00 €

Allegato 5: valutazione premialità pubblicazioni

[illegible]

Allegato 5: valutazione premialità pubblicazioni

Cognome Nome	Ruolo	SSD	Handle IRIS	Anno	Titolo	Note	Punti quartile	Punti autorialità	Riduzione + di 10 autori =puntix0,5	Riduzione review	Totale	Punti pubblicazioni	Punteggio ricercatore	Finanziamento
Doronzio Gabriella	TR		2318/1877591	2022	Transcription factor EB controls both mitogenic and mitogenic cell activities.	No fondi. All authors equally contributed to the preparation of this review. Pag 1977	2	1			3	17,5	0	0,00 €
Doronzio Gabriella	TR		2318/1877590	2022	The TFEB-TGIF1 axis regulates EMT in mouse epicardial cells.		3		0,5		1,5			0,00 €
Doronzio Gabriella	TR		2318/1871099	2022	TFEB controls integrin-mediated endothelial cell adhesion by the regulation of cholesterol metabolism	joint-last, corresponding. Pag. 471	3	1			4			0,00 €
Doronzio Gabriella	TR		2318/1869779	2021	TFEB Signalling-Related MicroRNAs and Autophagy.	last, corresponding. Pag. 1	2	1		0,5	1,5			0,00 €
Doronzio Gabriella	TR		2318/1789507	2021	The Oncogene Transcription Factor EB Regulates Vascular Functions.	first. Pag 1	2	1		0,5	1,5			0,00 €
Doronzio Gabriella	TR		2318/1788049	2021	Multifaceted activities of transcription factor EB in cancer onset and progression.	joint last. Pag 327	3	1		0,5	2			0,00 €
Doronzio Gabriella	TR		2318/1685458	2019	TFEB controls vascular development by regulating the proliferation of endothelial cells.	first and corresponding author.Pag 1	3	1			4			0,00 €
Doronzio Gabriella	TR													0,00 €
Doronzio Gabriella	TR													0,00 €
Doronzio Gabriella	TR													0,00 €
Germano Giovanni	RTDA	BIO/17	2318/1689662	2018	Inactivation of DNA repair-prospects for boosting cancer immune surveillance	Si fondi + Middle	3				3	22,5	22,5	5.120,10 €
Germano Giovanni	RTDA	BIO/17	2318/1740315	2018	The atypical chemokine receptor ACKR2 drives pulmonary fibrosis by tuning influx of CCR2+ and CCR5+ IFN γ -producing γ δ T cells in mice	Middle	3		0,5		1,5			0,00 €
Germano Giovanni	RTDA	BIO/17	2318/1675621	2018	SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo	Middle	3		0,5		1,5			0,00 €
Germano Giovanni	RTDA	BIO/17	2318/1660181	2018	Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer	First name	1	1			2			0,00 €
Germano Giovanni	RTDA	BIO/17	2318/1689636	2018	The Clinical Impact of the Genomic Landscape of Mismatch Repair-Deficient Cancers	First name	3	1		0,5	2			0,00 €
Germano Giovanni	RTDA	BIO/17	2318/1709286	2019	Evolving neoantigen profiles in colorectal cancers with DNA repair defects	Middle	3		0,5		1,5			0,00 €
Germano Giovanni	RTDA	BIO/17	2318/1740384	2020	High-dose Vitamin C enhances cancer immunotherapy	Co-First	3	1			4			0,00 €
Germano Giovanni	RTDA	BIO/17	2318/1794553	2021	Cd4 t cell-dependent rejection of beta-2 microglobulin null mismatch repair-deficient tumors	First and corresponding	3	1			4			0,00 €
Germano Giovanni	RTDA	BIO/17	2318/1794586	2021	Mechanisms of immune escape and resistance to checkpoint inhibitor therapies in mismatch repair deficient metastatic colorectal cancers	Last and corresponding	2	1		0,5	1,5			0,00 €
Germano Giovanni	RTDA	BIO/17	2318/1864543	2022	Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients	Middle	3		0,5		1,5			0,00 €
Grassi Elena	RTDA	INF/01	2318/1869160	2022	Chromatin Velocity reveals epigenetic dynamics by single-cell profiling of heterochromatin and euchromatin	No fondi	3		0,5		1,5	18,5	23,125	5.262,33 €
Grassi Elena	RTDA	INF/01	2318/1791282	2021	ESDN inhibits melanoma progression by blocking E-selectin expression in endothelial cells via STAT3		3	0	0,5		1,5			
Grassi Elena	RTDA	INF/01	2318/1894596	2021	PhyliCS: a Python library to explore scDNA data and quantify spatial tumor heterogeneity		3				3			
Grassi Elena	RTDA	INF/01	2318/1764702	2020	Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: The phase II HERACLES-B trial		2		0,5		1			

Allegato 5: valutazione premialità pubblicazioni

Cognome Nome	Ruolo	SSD	Handle IRIS	Anno	Titolo	Note	Punti quartile	Punti autorialità	Riduzione + di 10 autori =puntix0,5	Riduzione review	Totale	Punti pubblicazioni	Punteggio ricercatore	Finanziamento
Grassi Elena	RTDA	INF/01	2318/1750197	2020	Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype		3		0,5		1,5			
Grassi Elena	RTDA	INF/01	2318/1729463	2019	Choice of alternative polyadenylation sites, mediated by the rna-binding protein Elavl3, plays a role in differentiation of inhibitory neuronal progenitors		1	1			2			
Grassi Elena	RTDA	INF/01	2318/1724402	2019	The length of the expressed 3' UTR is an intermediate molecular phenotype linking genetic variants to complex disease		1				1			
Grassi Elena	RTDA	INF/01	2318/1718732	2019	FirstLife: Combining Social Networking and VGI to Create an Urban Coordination and Collaboration Platform		2				2			
Grassi Elena	RTDA	INF/01	2318/1663986	2018	Evolutionary Rewiring of Human Regulatory Networks by Waves of Genome Expansion		3				3			
Grassi Elena	RTDA	INF/01	2318/1880632	2022	Towards precision oncology with patient-derived xenografts	Joint first	3	1		0,5	2			
Isella Claudio	PA	BIO/17	2318/1768036	2021	Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts	No fondi + Co-last	3	1			4	19	23,75	5.404,55 €
Isella Claudio	PA	BIO/17	2318/1766965	2020	Improved Outcome Prediction for Appendiceal Pseudomyxoma Peritonei by Integration of Cancer Cell and Stromal Transcriptional Profiles	First	2	1			3			
Isella Claudio	PA	BIO/17	2318/1717860	2019	A Comprehensive PDX Gastric Cancer Collection Captures Cancer Cell-Intrinsic Transcriptional MSI Traits		3		0,5		1,5			
Isella Claudio	PA	BIO/17	2318/1670151	2018	High USP6NL Levels in Breast Cancer Sustain Chronic AKT Phosphorylation and GLUT1 Stability Fueling Aerobic Glycolysis		3		0,5		1,5			
Isella Claudio	PA	BIO/17	2318/1872224	2021	Molecular Subtyping Combined with Biological Pathway Analyses to Study Regorafenib Response in Clinically Relevant Mouse Models of Colorectal Cancer		3		0,5		1,5			
Isella Claudio	PA	BIO/17	2318/1728652	2020	A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin		3		0,5		1,5			
Isella Claudio	PA	BIO/17	2318/1715076	2019	Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer		3		0,5		1,5			
Isella Claudio	PA	BIO/17	2318/1750197	2020	Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype		3		0,5		1,5			
Isella Claudio	PA	BIO/17	2318/1856904	2022	A non-dividing cell population with high pyruvate dehydrogenase kinase activity regulates metabolic heterogeneity and tumorigenesis in the intestine		3		0,5		1,5			
Isella Claudio	PA	BIO/17	2318/1709286	2019	Evolving neoantigen profiles in colorectal cancers with DNA repair defects		3		0,5		1,5			
Kopecka Joanna	RTDB	BIO/10	2318/1711992	2019	Potential diagnostic and prognostic role of micro-environment in malignant pleural mesothelioma	Si fondi + joint-first	3	1			4	31	31	7.054,36 €
Kopecka Joanna	RTDB	BIO/10	2318/1712384	2019	Carbonic Anhydrase XII Inhibitors Overcome Temozolomide Resistance in Glioblastoma		3				3			0,00 €
Kopecka Joanna	RTDB	BIO/10	2318/1683405	2018	Increasing intratumor C/EBP-β LIP and nitric oxide levels overcome resistance to doxorubicin in triple negative breast cancer	joint-last	2	1			3			0,00 €
Kopecka Joanna	RTDB	BIO/10	2318/1845838	2022	SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma	joint-last	3	1			4			0,00 €

Allegato 5: valutazione premialità pubblicazioni

Cognome Nome	Ruolo	SSD	Handle IRIS	Anno	Titolo	Note	Punti quartile	Punti autorialità	Riduzione + di 10 autori =puntix0,5	Riduzione review	Totale	Punti pubblicazioni	Punteggio ricercatore	Finanziamento
Kopecka Joanna	RTDB	BIO/10	2318/1824284	2022	Click ferrocenyl-erlotinib conjugates active against erlotinib-resistant non-small cell lung cancer cells in vitro	joint-last	3	1			4			0,00 €
Kopecka Joanna	RTDB	BIO/10	2318/1824280	2021	Multifunctional thiosemicarbazones targeting sigma receptors: in vitro and in vivo antitumor activities in pancreatic cancer models	joint-first	2	1			3			0,00 €
Kopecka Joanna	RTDB	BIO/10	2318/1747154	2020	ABCA1/ABCB1 Ratio Determines Chemo- and Immune-Sensitivity in Human Osteosarcoma	joint-last	1	1			2			0,00 €
Kopecka Joanna	RTDB	BIO/10	2318/1665635	2018	Loss of C/EBP-β LIP drives cisplatin resistance in malignant pleural mesothelioma	joint-first	2	1			3			0,00 €
Kopecka Joanna	RTDB	BIO/10	2318/1747159	2020	Insights into P-Glycoprotein Inhibitors: New Inducers of Immunogenic Cell Death	first	1	1			2			0,00 €
Kopecka Joanna	RTDB	BIO/10	2318/1747161	2020	Small nucleolar RNAs determine resistance to doxorubicin in human osteosarcoma	joint-last	2	1			3			0,00 €
Levis Mario	RTDB	MED/36	2318/1858310	2022	An integrated approach to cardioprotection in lymphomas	No fondi + JOINT FIRST	3	1		0,5	2	26,5	33,125	7.537,93 €
Levis Mario	RTDB	MED/36	2318/1766013	2021	Safety of lung stereotactic ablative radiotherapy for the functioning of cardiac implantable electronic devices	FIRST and CORRESPONDING	3	1			4			
Levis Mario	RTDB	MED/36	2318/1846346	2021	Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: Final results of FIL HD0801 trial	CORRESPONDING	2	1			3			
Levis Mario	RTDB	MED/36	2318/1795801	2021	Efficacy of low-dose radiotherapy (2 Gy × 2) in the treatment of marginal zone and mucosa-associated lymphoid tissue lymphomas	LAST and CORRESPONDING	2	1			3			
Levis Mario	RTDB	MED/36	2318/1801870	2021	Adoption of Expansion Margins to Reduce the Dose Received by the Coronary Arteries and the Risk of Cardiovascular Events in Lymphoma Patients	CORRESPONDING	1	1			2			
Levis Mario	RTDB	MED/36	2318/1795637	2020	Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: A multi-institutional study of adult patients by ILROG	/	3		0,5		1,5			
Levis Mario	RTDB	MED/36	2318/1730636	2019	Salvage Treatment and Survival for Relapsed Follicular Lymphoma Following Primary Radiation Therapy: A Collaborative Study on Behalf of ILROG	/	3		0,5		1,5			
Levis Mario	RTDB	MED/36	2318/1730648	2019	Inclusion of heart substructures in the optimization process of volumetric modulated arc therapy techniques may reduce the risk of heart disease in Hodgkin's lymphoma patients	FIRST and CORRESPONDING	3	1			4			
Levis Mario	RTDB	MED/36	2318/1684780	2019	Definitive radiotherapy for localized follicular lymphoma staged by 18F-FDG PET-CT: a collaborative study by ILROG	/	3		0,5		1,5			
Levis Mario	RTDB	MED/36	2318/1682830	2018	Plan optimization for mediastinal radiotherapy: Estimation of coronary arteries motion with ECG-gated cardiac imaging and creation of compensatory expansion margins	FIRST and CORRESPONDING	3	1			4			
Listi Angela	TR		2318/1937370	2019	Immuno-targeted combinations in oncogene-addicted non-small cell lung cancer.	No fondi + first	0,5	0,5			1	10,75	13,4375	3.057,84 €
Listi Angela	TR		2318/1729987	2018	The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis	co-author	3		0,5		1,5			
Listi Angela	TR		2318/1895444	2023	Real-world retrospective study of KRAS mutations in advanced non-small cell lung cancer in the era of immunotherapy.	co-author	2				2			
Listi Angela	TR		2318/1874667	2022	RNA-based next-generation sequencing in non-small-cell lung cancer in a routine setting: an experience from an Italian referral center.	co-author	0,5		0,5		0,25			

Allegato 5: valutazione premialità pubblicazioni

Cognome Nome	Ruolo	SSD	Handle IRIS	Anno	Titolo	Note	Punti quartile	Punti autorialità	Riduzione + di 10 autori =puntix0,5	Riduzione review	Totale	Punti pubblicazioni	Punteggio ricercatore	Finanziamento
Listi Angela	TR		2318/1770386	2021	RNA-Based Assay for Next-Generation Sequencing of Clinically Relevant Gene Fusions in Non-Small Cell Lung Cancer.	co-author	2		0,5		1			
Listi Angela	TR		2318/1782184	2021	Dealing with NSCLC EGFR mutation testing and treatment: a comprehensive review with an Italian real-world perspective	co-author	3			0,5	1,5			
Listi Angela	TR		2318/1790907	2021	Mutational oncology of lung cancer: molecular markers, drugs, negotiation conditions and experiences in national reference centers.	co-author	0,5			0,5	0,25			
Listi Angela	TR		2318/1878603	2022	Diagnostics of BAP1-Tumor Predisposition Syndrome by a Multitestig Approach: A Ten-Year-Long Experience	co-author	0,5		0,5		0,25			
Listi Angela	TR		2318/1937410	2020	NUPR1 interacts with eIF2 α and is required for resolution of the ER stress response in pancreatic tissue	co-author	2				2			
Listi Angela	TR		2318/1790638	2021	Clinical and Molecular Features of Epidermal Growth Factor Receptor (EGFR) Mutation Positive Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Tyrosine Kinase Inhibitors (TKIs): Predictive and Prognostic Role of Co-Mutations.	co-author	2		0,5		1			
Lorenzato Annalisa	TR		2318/1675615	2018	Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer	No fondi	3		0,5		1,5	16,5	20,625	4.693,43 €
Lorenzato Annalisa	TR		2318/1740384	2020	High-dose Vitamin C enhances cancer immunotherapy		3		0,5		1,5			0,00 €
Lorenzato Annalisa	TR		2318/1768356	2020	Extracellular vesicles in human preterm colostrum inhibit infection by human cytomegalovirus in vitro		1		0,5		0,5			0,00 €
Lorenzato Annalisa	TR		2318/1740015	2020	EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer		3		0,5		1,5			0,00 €
Lorenzato Annalisa	TR		2318/1728652	2019	A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin		3		0,5		1,5			0,00 €
Lorenzato Annalisa	TR		2318/1675614	2018	Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies		3		0,5		1,5			0,00 €
Lorenzato Annalisa	TR		2318/1738329	2020	Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer	first	2	1			3			0,00 €
Lorenzato Annalisa	TR		2318/1709286	2019	Evolving neoantigen profiles in colorectal cancers with DNA repair defects	joint first	3	1			4			0,00 €
Lorenzato Annalisa	TR		2318/1872758	2022	Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer		3		0,5		1,5			0,00 €
Lorenzato Annalisa	TR													0,00 €
Maione Federica	RTDA	BIO/12		2022	The neuronal protein Neuroligin 1 promotes colorectal cancer progression by modulating the APC/ β -catenin pathway. r		3		0,5		1,5	18,5	23,125	5.262,33 €
Maione Federica	RTDA	BIO/12		2022	Albumin nanoformulations as an innovative solution to overcome doxorubicin chemoresistance		1				1			0,00 €
Maione Federica	RTDA	BIO/12		2022	Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression.		2		0,5		1			0,00 €
Maione Federica	RTDA	BIO/12		2022	Inducible T-Cell Costimulator Ligand Plays a Dual Role in Melanoma Metastasis upon Binding to Osteopontin or Inducible T-Cell Costimulator		2		0,5		1			0,00 €
Maione Federica	RTDA	BIO/12		2020	Osteopontin binds ICOSL promoting tumor metastasis		3		0,5		1,5			0,00 €

Allegato 5: valutazione premialità pubblicazioni

Cognome Nome	Ruolo	SSD	Handle IRIS	Anno	Titolo	Note	Punti quartile	Punti autorialità	Riduzione + di 10 autori =puntix0,5	Riduzione review	Totale	Punti pubblicazioni	Punteggio ricercatore	Finanziamento
Maione Federica	RTDA	BIO/12		2020	HIV Protease Inhibitors Block HPV16-Induced Murine Cervical Carcinoma and Promote Vessel Normalization in Association with MMP-9 Inhibition and TIMP-3 Induction	Joint first	2	1			3			0,00 €
Maione Federica	RTDA	BIO/12		2020	CAR T cells targeting tumor endothelial marker CLEC14A inhibit tumor growth		3		0,5		1,5			0,00 €
Maione Federica	RTDA	BIO/12		2018	Therapeutic Silencing of miR-214 Inhibits Tumor Progression in Multiple Mouse Models		3				3			0,00 €
Maione Federica	RTDA	BIO/12		2018	A rationally designed NRP1-independent superagonist SEMA3A mutant is an effective anticancer agent	Joint first	3	1			4			0,00 €
Maione Federica	RTDA	BIO/12		2018	α -ketoglutarate dehydrogenase inhibition counteracts breast cancer-associated lung metastasis		2		0,5		1			0,00 €
Manfredi Matteo	PA	MED/24	2318/1647220	2018	Chitosan membranes applied on the prostatic neurovascular bundles after nerve-sparing robot-assisted radical prostatectomy: a phase II study	No fondi.	3				3	25,5	31,875	7.253,48 €
Manfredi Matteo	PA	MED/24	2318/1711047	2019	Total anatomical reconstruction during robot-assisted radical prostatectomy: focus on urinary continence recovery and related complications after 1000 procedures	First	3	1			4			
Manfredi Matteo	PA	MED/24	2318/1691034	2019	Use of chitosan membranes after nerve-sparing radical prostatectomy improves early recovery of sexual potency: results of a comparative study		3		0,5		1,5			
Manfredi Matteo	PA	MED/24	2318/1797888	2019	Three-dimensional virtual imaging of renal tumours: a new tool to improve the accuracy of nephrometry scores		3				3			
Manfredi Matteo	PA	MED/24	2318/1711060	2019	Three-dimensional Elastic Augmented-reality Robot-assisted Radical Prostatectomy Using Hyperaccuracy Three-dimensional Reconstruction Technology: A Step Further in the Identification of Capsular Involvement		3		0,5		1,5			
Manfredi Matteo	PA	MED/24	2318/1711058	2019	Total anatomical reconstruction during robot-assisted radical prostatectomy in patients with previous prostate surgery		2				2			
Manfredi Matteo	PA	MED/24	2318/1738073	2019	Laparoscopic simple prostatectomy: complications and functional results after 5 years of follow-up	First	2	1			3			
Manfredi Matteo	PA	MED/24	2318/1888441	2021	Diagnostic Accuracy of Single-plane Biparametric and Multiparametric Magnetic Resonance Imaging in Prostate Cancer: A Randomized Noninferiority Trial in Biopsy-naïve Men		3				3			
Manfredi Matteo	PA	MED/24	2318/1759731	2021	Urethral-sparing Robot-assisted Simple Prostatectomy: An Innovative Technique to Preserve Ejaculatory Function Overcoming the Limitation of the Standard Millin Approach		3				3			
Manfredi Matteo	PA	MED/24	2318/1850719	2022	Percutaneous Kidney Puncture with Three-dimensional Mixed-reality Hologram Guidance: From Preoperative Planning to Intraoperative Navigation		3		0,5		1,5			
Merlini Alessandra	RTDA	MED/06	2318/1887827	2022	A prospective observational study of active surveillance in primary desmoid fibromatosis.		3		0,5		1,5	19,5	0	0,00 €
Merlini Alessandra	RTDA	MED/06	2318/1878035	2022	Biological and Exploitable Crossroads for the Immune Response in Cancer and COVID-19.	Joint first	2	1		0,5	1,5			0,00 €

Allegato 5: valutazione premialità pubblicazioni

[illegible]

Allegato 5: valutazione premialità pubblicazioni

Cognome Nome	Ruolo	SSD	Handle IRIS	Anno	Titolo	Note	Punti quartile	Punti autorialità	Riduzione + di 10 autori =puntix0,5	Riduzione review	Totale	Punti pubblicazioni	Punteggio ricercatore	Finanziamento
Monica Valentina	RTDA	BIO/10	2318/1873921	2022	Immunohistochemistry with 3 different clones in anaplastic lymphoma kinase fluorescence in situ hybridization positive non-small-cell lung cancer with thymidylate synthase expression analysis: a multicentre, retrospective, Italian study	Si fondi attivi	1		0,5		0,5	9,25	9,25	2.104,93 €
Monica Valentina	RTDA	BIO/10	2318/1858906	2022	Iron metabolism in the social amoeba Dictyostelium discoideum: A role for ferric chelate reductases		2				2			0,00 €
Monica Valentina	RTDA	BIO/10	2318/1814652	2022	International Tailored Chemotherapy Adjuvant (ITACA) Trial, a Phase III Multicenter Randomized Trial Comparing Adjuvant Pharmacogenomic-Driven Chemotherapy versus Standard Adjuvant Chemotherapy in completely Resected Stage II-IIIa Non-Small Cell Lung Cancer		3		0,5		1,5			0,00 €
Monica Valentina	RTDA	BIO/10	2318/1763075	2020	Calcitriol Inhibits Viability and Proliferation in Human Malignant Pleural Mesothelioma Cells		2		0,5		1			0,00 €
Monica Valentina	RTDA	BIO/10	2318/1775041	2020	A pilot study of next generation sequencing–liquid biopsy on cell-free DNA as a novel non-invasive diagnostic tool for Klippel–Trenaunay syndrome		0,5		0,5		0,25			0,00 €
Monica Valentina	RTDA	BIO/10	2318/1729742	2020	Activation of RSK by phosphomimetic substitution in the activation loop is prevented by structural constraints		3		0,5		1,5			0,00 €
Monica Valentina	RTDA	BIO/10	2318/1729756	2019	Dynamic Interplay between Pericytes and Endothelial Cells during Sprouting Angiogenesis		1				1			0,00 €
Monica Valentina	RTDA	BIO/10	2318/1650666	2018	Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.		3		0,5		1,5			0,00 €
Monica Valentina	RTDA	BIO/10												0,00 €
Monica Valentina	RTDA	BIO/10												0,00 €
Passiglia Francesco	PA	MED/06	2318/1770085	2020	Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations	Fondi attivi (CRT). Co-first	3	1		0,5	2	22	22	5.006,32 €
Passiglia Francesco	PA	MED/06	2318/1797359	2021	Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A systematic Review and Metanalysis		3	1		0,5	2			0,00 €
Passiglia Francesco	PA	MED/06	2318/1851162	2021	Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC ? A trial level metanalysis in PD-L1 selected subgroups		1	1			2			0,00 €
Passiglia Francesco	PA	MED/06	2318/1878034	2022	Comparing T Cell Subsets in Broncho-Alveolar Lavage (BAL) and Peripheral Blood in Patients with Advanced Lung Cancer		2		0,5		1			0,00 €
Passiglia Francesco	PA	MED/06	2318/1797358	2021	Repositioning PARP inhibitors in the treatment of thoracic malignancies		3	1		0,5	2			0,00 €
Passiglia Francesco	PA	MED/06	2318/1719884	2019	Lung Cancer in Italy	Editorial material	0	0			0			0,00 €
Passiglia Francesco	PA	MED/06	2318/1692431	2018	Circulating programmed death ligand-1 (cPD-L1) in non-small- cell lung cancer (NSCLC)	Co-first	2	1			3			0,00 €
Passiglia Francesco	PA	MED/06	2318/1693320	2019	Efficacy of nivolumab in pre-treated non-small cell lung cancer patients harbouring KRAS mutations		3	1			4			0,00 €
Passiglia Francesco	PA	MED/06	2318/1729987	2018	The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis.		3	1		0,5	2			0,00 €

Allegato 5: valutazione premialità pubblicazioni

Cognome Nome	Ruolo	SSD	Handle IRIS	Anno	Titolo	Note	Punti quartile	Punti autorialità	Riduzione + di 10 autori =puntix0,5	Riduzione review	Totale	Punti pubblicazioni	Punteggio ricercatore	Finanziamento
Passiglia Francesco	PA	MED/06	2318/1692984	2018	Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab		3	1			4			0,00 €
Puliafito Alberto	PA	BIO/10	2318/1729722	2019	Self-Organized Nuclear Positioning Synchronizes the Cell Cycle in Drosophila Embryos	Fondi SI. Joint-first	3	1			4	24	24	5.461,44 €
Puliafito Alberto	PA	BIO/10	2318/1750197	2020	Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype		3		0,5		1,5			0,00 €
Puliafito Alberto	PA	BIO/10	2318/1792133	2021	Recruitment, infiltration and cytotoxicity of hla-independent killer lymphocytes in three-dimensional melanoma models	Joint-last	2	1			3			0,00 €
Puliafito Alberto	PA	BIO/10	2318/1729756	2019	Dynamic Interplay between Pericytes and Endothelial Cells during Sprouting Angiogenesis	Joint-last	1	1			2			0,00 €
Puliafito Alberto	PA	BIO/10	2318/1729762	2019	Driving Cells with Light-Controlled Topographies	First	3	1			4			0,00 €
Puliafito Alberto	PA	BIO/10	2318/1662907	2018	MRCKalpha is activated by caspase cleavage to assemble an apical actin ring for epithelial cell extrusion		3				3			0,00 €
Puliafito Alberto	PA	BIO/10	2318/1662906	2018	PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations		2				2			0,00 €
Puliafito Alberto	PA	BIO/10	2318/1869137	2022	A modified fluctuation-test framework characterizes the population dynamics and mutation rate of colorectal cancer persister cells		3		0,5		1,5			0,00 €
Puliafito Alberto	PA	BIO/10	2318/1685458	2019	TFEB controls vascular development by regulating the proliferation of endothelial cells		3		0,5		1,5			0,00 €
Puliafito Alberto	PA	BIO/10	2318/1729742	2020	Activation of RSK by phosphomimetic substitution in the activation loop is prevented by structural constraints		3		0,5		1,5			0,00 €
Reddavid Rossella	RUTDA	MED/18	2318/1659652	2018	Neoadjuvant chemotherapy for gastric cancer. Is it a must or a fake?	First	2	1		0,5	1,5	20,5	25,625	5.831,23 €
Reddavid Rossella	RUTDA	MED/18	2318/1823859	2022	Risk factors for anastomotic leakage after anterior resection for rectal cancer (RALAR study): A nationwide retrospective study of the Italian Society of Surgical Oncology Colorectal Cancer Network Collaborative Group	Last	2	1			3			0,00 €
Reddavid Rossella	RUTDA	MED/18	2318/1794901	2021	Upper GI training of young surgeons: a reality full of hurdles. An international survey	First	1	1			2			0,00 €
Reddavid Rossella	RUTDA	MED/18	2318/1870719	2022	Complete mesocolic excision in comparison with conventional surgery for right colon cancer: a nationwide multicenter study of the Italian Society of Surgical Oncology colorectal cancer network (CoME-in trial). Study protocol for a randomized controlled trial	Last	1	1			2			0,00 €
Reddavid Rossella	RUTDA	MED/18	2318/1759729	2020	Intracorporeal Stapled Ileocolic Anastomosis with Mechanical Closure of the Enterotomy After Minimally Invasive Right Colectomy for Cancer: Introduction of a New Technique	First. Note, editorial material	0	0			0			0,00 €
Reddavid Rossella	RUTDA	MED/18	2318/1794900	2019	Non-anatomical colonic resections: Splenic flexure and transverse colectomy Central vascular ligation is crucial for survival	First	0,5	0,5			1			0,00 €
Reddavid Rossella	RUTDA	MED/18	2318/1873722	Epub 2022	Minimally invasive vs. open segmental resection of the splenic flexure for cancer: a nationwide study of the Italian Society of Surgical Oncology-Colorectal Cancer Network (SICO-CNN)	Last	3	1			4			0,00 €

Allegato 5: valutazione premialità pubblicazioni

Cognome Nome	Ruolo	SSD	Handle IRIS	Anno	Titolo	Note	Punti quartile	Punti autorialità	Riduzione + di 10 autori =puntix0,5	Riduzione review	Totale	Punti pubblicazioni	Punteggio ricercatore	Finanziamento
Reddavid Rossella	RUTDA	MED/18	2318/1708865	2019	Transhiatal distal esophagectomy for Siewert type II cardia cancer can be a treatment option in selected patients	First	3	1			4			0,00 €
Reddavid Rossella	RUTDA	MED/18	2318/1799235	2021	Molecularly targeted therapies for gastric cancer. State of the art	First	2	1		0,5	1,5			0,00 €
Reddavid Rossella	RUTDA	MED/18	2318/1759726	2020	Patient-Derived Orthotopic Xenograft models in gastric cancer: a systematic review	First	2	1		0,5	1,5			0,00 €
Russo Mariangela	RTDB	BIO/17	2318/1869137	2022	A modified fluctuation-test framework characterizes the population dynamics and mutation rate of colorectal cancer persister cells. DOI: 10.1038/s41588-022-01105-z. pp.1-26. In NATURE GENETICS	First	3	1			4	19	19	4.323,64 €
Russo Mariangela	RTDB	BIO/17	2318/1792716	2021	Adaptive Evolution: How Bacteria and Cancer Cells Survive Stressful Conditions and Drug Treatment. doi: 10.1158/2159-8290.CD-20-1588. pp. 1-11. In CANCER DISCOVERY	First/co-corresponding	3	1			4			0,00 €
Russo Mariangela	RTDB	BIO/17	2318/1728652	2019	A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin. DOI:10.1158/1078-0432.CCR-19-2409. pp.1-14. In CLINICAL CANCER RESEARCH - ISSN:1078-0432		3		0,5		1,5			0,00 €
Russo Mariangela	RTDB	BIO/17	2318/1725664	2019	Adaptive mutability of colorectal cancers in response to targeted therapies. DOI:10.1126/science.aav4474. pp.1473-1480. In SCIENCE - ISSN:0036-8075 vol. 366 (6472)	First/co-corresponding	3	1			4			0,00 €
Russo Mariangela	RTDB	BIO/17	2318/1675615	2018	Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer. DOI:10.1016/j.ccell.2018.06.004. pp.148-162.e7. In CANCER CELL - ISSN:1535-6108 vol. 34 (1)		3		0,5		1,5			0,00 €
Russo Mariangela	RTDB	BIO/17	2318/1675614	2018	Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies. DOI:10.1038/s41467-018-04506-z. pp.2287-2298. In NATURE COMMUNICATIONS - ISSN:2041-1723 vol. 9 (1)	First/co-corresponding	3	1			4			0,00 €
Russo Mariangela	RTDB	BIO/17												0,00 €
Russo Mariangela	RTDB	BIO/17												0,00 €
Russo Mariangela	RTDB	BIO/17												0,00 €
Russo Mariangela	RTDB	BIO/17												0,00 €
Russo Mariangela	RTDB	BIO/17												0,00 €
Russotto Vincenzo	RTDB	MED/41	2318/1789178	2021	Intubation Practices and Adverse Peri-intubation Events in Critically Ill Patients from 29 Countries	FIRST	3	1			4	24	30	6.826,80 €
Russotto Vincenzo	RTDB	MED/41	2318/1867078	2022	Peri-intubation Cardiovascular Collapse in Critically Ill Patients: Insights from the INTUBE Study	FIRST	3	1			4			
Russotto Vincenzo	RTDB	MED/41	2318/1869111	2021	Helmet and face mask for non-invasive respiratory support in patients with acute hypoxemic respiratory failure: A retrospective study		2				2			
Russotto Vincenzo	RTDB	MED/41	2318/1815384	2021	Thromboelastometry, Thromboelastography, and Conventional Tests to Assess Anticoagulation during Extracorporeal Support: A Prospective Observational Study		1				1			
Russotto Vincenzo	RTDB	MED/41	2318/1850365	2021	Tracheal intubation in the critically ill patient	FIRST	2	1		0,5	1,5			

Allegato 5: valutazione premialità pubblicazioni

Cognome Nome	Ruolo	SSD	Handle IRIS	Anno	Titolo	Note	Punti quartile	Punti autorialità	Riduzione + di 10 autori =punti0,5	Riduzione review	Totale	Punti pubblicazioni	Punteggio ricercatore	Finanziamento
Rusotto Vincenzo	RTDB	MED/41	2318/1867079	2022	Short and long-term complications due to standard and extended prone position cycles in CoViD-19 patients		3		0,5		1,5			
Rusotto Vincenzo	RTDB	MED/41	2318/1850308	2019	What's new in airway management of the critically ill	FIRST	3	1			4			
Rusotto Vincenzo	RTDB	MED/41	2318/1850318	2018	Respiratory mechanics in patients with acute respiratory distress syndrome	FIRST	1	1		0,5	1			
Rusotto Vincenzo	RTDB	MED/41	2318/1850313	2020	Management of critically ill patients with covid-19: suggestions and instructions from the coordination of intensive care units of lombardy	CORRESPONDING	1	1			2			
Rusotto Vincenzo	RTDB	MED/41	2318/1850298	2018	Development of a prediction model for postoperative pneumonia: A multicentre prospective observational study	FIRST	2	1			3			
Senetta Rebecca	PA	MED/08	2318/1863379	2022	Clinical-Pathological Evaluation and Prognostic Analysis of 228 Merkel Cell Carcinomas Focusing on Tumor-Infiltrating Lymphocytes, MCPYV Infection and ALK Expression	Corresponding; Joint last	3	1			4	13,5	16,875	3.840,08 €
Senetta Rebecca	PA	MED/08	2318/1844146	2022	Sézary Syndrome: Different Erythroderma Morphological Features with Proposal for a Clinical Score System.		2		0,5		1			0,00 €
Senetta Rebecca	PA	MED/08	2318/1815260	2021	Non-Sentinel Lymph Node Detection during Sentinel Lymph Node Biopsy in Not-Complete-Lymph-Node-Dissection Era: A New Technique for Better Staging and Treating Melanoma Patients.		2		0,5		1			0,00 €
Senetta Rebecca	PA	MED/08	2318/1858947	2021	NTRK Gene Fusion Detection in Atypical Spitz Tumors.		2		0,5		1			0,00 €
Senetta Rebecca	PA	MED/08	2318/1795380	2021	Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition.		3		0,5		1,5			0,00 €
Senetta Rebecca	PA	MED/08	2318/1792813	2021	The Molecular Landscape of Primary Acral Melanoma: A Multicenter Study of the Italian Melanoma Intergroup (IMI)		2		0,5		1			0,00 €
Senetta Rebecca	PA	MED/08	2318/1759688	2021	Microenvironment in cutaneous melanomas: a gene expression profile study may explain the role of histological regression.	E' una letter	0				0			0,00 €
Senetta Rebecca	PA	MED/08	2318/1762348	2021	The prognostic impact of the extent of ulceration in patients with clinical stage I-II melanoma: a multicentre study of the Italian Melanoma Intergroup (IMI).		3		0,5		1,5			0,00 €
Senetta Rebecca	PA	MED/08	2318/1762340	2020	Defining the Prognostic Role of MicroRNAs in Cutaneous Melanoma.		3		0,5		1,5			0,00 €
Senetta Rebecca	PA	MED/08	2318/1695898	2019	TERT Promoter Mutations are Associated with Visceral Spreading in Melanoma of the Trunk		2		0,5		1			0,00 €
Taulli Riccardo	PA	BIO/10	2318/1790637	2021	Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma		2		0,5		1	11,5	11,5	2.616,94 €
Taulli Riccardo	PA	BIO/10	2318/1787263	2021	IκBε targeting promotes oxidative stress-dependent cell death.		3		0,5		1,5			0,00 €
Taulli Riccardo	PA	BIO/10	2318/1794750	2020	Future perspectives from lung cancer pre-clinical models: new treatments are coming?	last	2	1		0,5	1,5			0,00 €
Taulli Riccardo	PA	BIO/10	2318/1737284	2020	p53 vs NF-κB: the role of nuclear factor-kappa B in the regulation of p53 activity and vice versa		3			0,5	1,5			0,00 €
Taulli Riccardo	PA	BIO/10	2318/1747161	2020	Small Nucleolar RNAs Determine Resistance to Doxorubicin in Human Osteosarcoma		2		0,5		1			0,00 €
Taulli Riccardo	PA	BIO/10	2318/1737289	2020	Tumor Suppressors in Chronic Lymphocytic Leukemia: From Lost Partners to Active Targets	co-last	2	1		0,5	1,5			0,00 €
Taulli Riccardo	PA	BIO/10	2318/1719484	2020	Inhibition of bromodomain and extra-terminal proteins increases sensitivity to venetoclax in chronic lymphocytic leukaemia		1		0,5		0,5			0,00 €

Allegato 5: valutazione premialità pubblicazioni

Cognome Nome	Ruolo	SSD	Handle IRIS	Anno	Titolo	Note	Punti quartile	Punti autorialità	Riduzione + di 10 autori =puntix0,5	Riduzione review	Totale	Punti pubblicazioni	Punteggio ricercatore	Finanziamento
Taulli Riccardo	PA	BIO/10	2318/1868961	2022	MET Inhibition Sensitizes Rhabdomyosarcoma Cells to NOTCH Signaling Suppression		1		0,5		0,5			0,00 €
Taulli Riccardo	PA	BIO/10	2318/1845838	2022	SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma		3		0,5		1,5			0,00 €
Taulli Riccardo	PA	BIO/10	2318/1858943	2022	Micro-RNA-215 and -375 regulate thymidylate synthase protein expression in pleural mesothelioma and mediate epithelial to mesenchymal transition		2		0,5		1			0,00 €
														0,00 €
														0,00 €
														0,00 €
														0,00 €
														0,00 €
														0,00 €
														0,00 €
														0,00 €
														0,00 €
														0,00 €
Legenda colori No fondi = si applica moltiplicatore 1,25 Fondi attivi = non si applica moltiplicatore												Totale punti	593,25	135.000,00 €
												Assegnazione	135.000,00 €	
												Euro/punto	227,56 €	